viewMaxCyte Inc

Growing MaxCyte bolsters leadership team with three senior appointments

Key among them was the promotion of Brad Calvin to the role of chief commercial officer

MaxCyte Inc -

MaxCyte Inc (LON:MXCT) has announced three senior appointments that it said “bolstered the leadership team”.

Key among them was the promotion of Brad Calvin to the role of chief commercial officer after a successful stint as the cell therapy specialist’s vice president of commercial operations.

In his former role, Calvin oversaw the sales, marketing and business development functions and MaxCyte said he helped “define product strategy, deliver new products and drove the growth of its drug discovery and cell therapy businesses”.

Specifically, he led the successful launch of the ExPERT platform, a family of instruments used in complex cellular engineering.

In a statement, MaxCyte chief executive Doug Doerfler said: “Brad’s promotion is well-earned and important for MaxCyte’s future growth. Since joining MaxCyte in 2017, he has forged pivotal relationships with leading cell therapy and gene editing companies, leading to multiple successful clinical and commercial agreements.

MaxCyte announced two further appointments – Sarah Haecker Meeks, who has joined as vice president, business development, while Steve Nardi has been appointed vice president of the firm’s manufacturing and engineering operations. 

“Sarah’s extensive corporate development experience across the gene and cell therapy sector and Steve’s broad knowledge of innovative manufacturing strategy and R&D will help MaxCyte continue to extend the reach of its next-generation cell engineering technologies,” said CEO Doerfler.

“These technologies hold great promise for global drug development companies working on breakthrough therapies for patients.”

Quick facts: MaxCyte Inc


Price: 1015 GBX

Market Cap: £1.02 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Maxcyte revenues rise 21%, hailing three new strategic licences with cell...

Proactive Research analyst Emma Ulker discusses MaxCyte's (LON:MXCT) commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US $26.2mln in fiscal (FY) 2020.  Ulker says this included three new strategic licences with high profile cell therapy...

on 29/4/21

2 min read